36氪精选：硅谷富豪，开始定制「超级后代」

Core Viewpoint - The article discusses the emerging trend of genetic selection in Silicon Valley, where wealthy individuals are increasingly using advanced genetic testing technologies to select embryos based on desirable traits, including intelligence and physical attributes, raising significant ethical concerns [6][9][12]. Group 1: Genetic Testing Technologies - PGT (Preimplantation Genetic Testing) has evolved from basic genetic disease screening to more complex assessments, including PGT-P, which can predict multiple genetic conditions and traits [9][10]. - PGT-M focuses on single-gene disorders, PGT-A on aneuploidy, and PGT-SR on chromosomal structural abnormalities [8]. Group 2: Market Dynamics and Key Players - Companies like Orchid and Herasight are at the forefront of this trend, offering services that include intelligence screening for embryos, with significant backing from venture capital [10][11]. - Nucleus Genomics has created a "gene store" where prospective parents can select from over 2000 diseases and various traits, reflecting a shift towards commodifying genetic selection [12]. Group 3: Ethical Implications - The article highlights the potential dangers of treating genetic traits as determinants of personal worth, which could lead to societal divisions based on genetic "perfection" [12][13]. - The narrative draws parallels to the film "Gattaca," illustrating the risks of a future where genetic selection leads to a stratified society [12].